## Paul G Unschuld

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5322932/publications.pdf

Version: 2024-02-01

172457 144013 3,557 77 29 57 citations h-index g-index papers 83 83 83 6149 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age. Frontiers in Aging Neuroscience, 2022, 14, 811146.	3.4	5
2	Physical activity is associated with lower cerebral beta-amyloid and cognitive function benefits from lifetime experience–a study in exceptional aging. PLoS ONE, 2021, 16, e0247225.	2.5	10
3	EEG-fMRI Signal Coupling Is Modulated in Subjects With Mild Cognitive Impairment and Amyloid Deposition. Frontiers in Aging Neuroscience, 2021, 13, 631172.	3.4	5
4	The A/T/N model applied through imaging biomarkers in a memory clinic. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 247-255.	6.4	23
5	Alzheimer's disease biomarker roadmap 2020: [ 18 F]flortaucipir. Alzheimer's and Dementia, 2020, 16, e039550.	0.8	O
6	Alzheimer's disease biomarker roadmap 2020: Secondâ€generation tau PET tracers. Alzheimer's and Dementia, 2020, 16, e039556.	0.8	1
7	Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. Alzheimer's and Dementia, 2020, 16, e039557.	0.8	2
8	Betaâ€amyloidâ€associated episodic memory variation correlates with subicular volume in nonâ€demented old aged individuals. Alzheimer's and Dementia, 2020, 16, e043904.	0.8	0
9	GABA and glutamate associate with evidence of preclinical Alzheimer disease in humans: A 7 Tesla MRSI and <sup>11</sup> Câ€PIB PET study. Alzheimer's and Dementia, 2020, 16, e044175.	0.8	1
10	Alzheimer's disease biomarker roadmap 2020: Time for tau. Alzheimer's and Dementia, 2020, 16, e039549.	0.8	3
11	Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β-amyloid, Tau, and APOE4. Frontiers in Aging Neuroscience, 2020, 12, 46.	3.4	21
12	Brain areas with normatively greater cerebral perfusion in early life may be more susceptible to beta amyloid deposition in late life. Cerebral Circulation - Cognition and Behavior, 2020, 1, 100001.	0.9	1
13	APOE4 moderates effects of cortical iron on synchronized default mode network activity in cognitively healthy oldâ€aged adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12002.	2.4	23
14	Reduced uptake of [11C]â€ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer's dementia. Brain and Behavior, 2020, 10, e01632.	2.2	14
15	Differential Changes in Arteriolar Cerebral Blood Volume between Parkinson's Disease Patients with Normal and Impaired Cognition and Mild Cognitive Impairment (MCI) Patients without Movement Disorder—An Exploratory Study. Tomography, 2020, 6, 333-342.	1.8	7
16	GABA and glutamate moderate beta-amyloid related functional connectivity in cognitively unimpaired old-aged adults. Neurolmage: Clinical, 2019, 22, 101776.	2.7	28
17	Increased cerebral blood volume in small arterial vessels is aÂcorrelate of amyloid-β–related cognitive decline. Neurobiology of Aging, 2019, 76, 181-193.	3.1	10
18	Novel Translational Research Methodology and the Prospect to a Better Understanding of Neurodegenerative Disease. Neurodegenerative Diseases, 2018, 18, 1-4.	1.4	4

#	Article	IF	CITATIONS
19	Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old. Neurobiology of Aging, 2018, 64, 68-75.	3.1	25
20	Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and $\hat{l}^2$ -amyloid as an indicator of cognitive performance at high age. NeuroImage, 2018, 174, 308-316.	4.2	70
21	Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults. Neurobiology of Aging, 2018, 63, 152-161.	3.1	16
22	Tau PET imaging evidence in patients with cognitive impairment: preparing for clinical use. Clinical and Translational Imaging, 2018, 6, 471-482.	2.1	3
23	Hybrid PET-MRI in Alzheimer's Disease Research. Methods in Molecular Biology, 2018, 1750, 185-200.	0.9	16
24	Abnormal Grey Matter Arteriolar Cerebral Blood Volume in Schizophrenia Measured With 3D Inflow-Based Vascular-Space-Occupancy MRI at 7T. Schizophrenia Bulletin, 2017, 43, sbw109.	4.3	28
25	Memory performance-related dynamic brain connectivity indicates pathological burden and genetic risk for Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 24.	6.2	43
26	Hippocampal shape alterations are associated with regional ${\sf A}\hat{\sf I}^2$ load in cognitively normal elderly individuals. European Journal of Neuroscience, 2017, 45, 1241-1251.	2.6	9
27	[ICâ€Pâ€018]: NEUROIMAGINGâ€DEFINED AMYLOID AND CEREBROVASCULAR PATHOLOGY ARE ASSOCIATED W NEUROMETABOLIC SIGNATURE OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P20.	/ITHA	O
28	Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients. Frontiers in Aging Neuroscience, 2017, 9, 38.	3.4	43
29	Changes of Functional and Directed Resting-State Connectivity Are Associated with Neuronal Oscillations, ApoE Genotype and Amyloid Deposition in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2017, 9, 304.	3.4	32
30	Low episodic memory performance in cognitively normal elderly subjects is associated with increased posterior cingulate gray matter N-acetylaspartate: a 1H MRSI study at 7ÂTesla. Neurobiology of Aging, 2016, 48, 195-203.	3.1	24
31	Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment. Scientific Reports, 2016, 6, 35514.	3.3	147
32	Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease. Current Opinion in Neurology, 2016, 29, 749-755.	3.6	10
33	Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A 1H MRS Study at 7Tesla. Schizophrenia Research, 2016, 172, 101-105.	2.0	67
34	Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease. American Journal of Neuroradiology, 2016, 37, 789-796.	2.4	107
35	Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. Neurobiology of Aging, 2015, 36, 1619-1628.	3.1	41
36	Regional Fluid-Attenuated Inversion Recovery (FLAIR) at 7 Tesla correlates with amyloid beta in hippocampus and brainstem of cognitively normal elderly subjects. Frontiers in Aging Neuroscience, 2014, 6, 240.	3.4	20

#	Article	IF	CITATIONS
37	Elevated arteriolar cerebral blood volume in prodromal Huntington's disease. Movement Disorders, 2014, 29, 396-401.	3.9	47
38	Prefrontal Brain Network Connectivity Indicates Degree of Both Schizophrenia Risk and Cognitive Dysfunction. Schizophrenia Bulletin, 2014, 40, 653-664.	4.3	69
39	Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 2014, 10, 204-216.	10.1	873
40	Cortical Amyloid Beta in Cognitively Normal Elderly Adults is Associated with Decreased Network Efficiency within the Cerebro-Cerebellar System. Frontiers in Aging Neuroscience, 2014, 6, 52.	3.4	26
41	Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels. European Neuropsychopharmacology, 2013, 23, 653-662.	0.7	32
42	Thursday Abstracts. Biological Psychiatry, 2013, 73, 1S-110S.	1.3	0
43	Gross feature recognition of Anatomical Images based on Atlas grid (GAIA): Incorporating the local discrepancy between an atlas and a target image to capture the features of anatomic brain MRI. Neurolmage: Clinical, 2013, 3, 202-211.	2.7	10
44	Prefrontal executive function associated coupling relates to Huntington's disease stage. Cortex, 2013, 49, 2661-2673.	2.4	31
45	Quantification of subcortical grayâ€matter vascularization using 7Â <scp>T</scp> esla timeâ€ofâ€flight angiography. Brain and Behavior, 2013, 3, 515-518.	2.2	3
46	Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction. Pharmacopsychiatry, 2013, 46, .	3.3	2
47	Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex. Psychiatry Research - Neuroimaging, 2012, 203, 166-174.	1.8	37
48	Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease. Neuroscience Letters, 2012, 514, 204-209.	2.1	101
49	Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Movement Disorders, 2012, 27, 895-902.	3.9	71
50	TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Molecular Psychiatry, 2011, 16, 647-663.	7.9	130
51	Adenosine A2A receptor gene: Evidence for association of risk variants with panic disorder and anxious personality. Journal of Psychiatric Research, 2010, 44, 930-937.	3.1	90
52	Variations in tryptophan hydroxylase 2 linked to decreased serotonergic activity are associated with elevated risk for metabolic syndrome in depression. Molecular Psychiatry, 2010, 15, 736-747.	7.9	29
53	Gender-Specific Association of Galanin Polymorphisms with HPA-Axis Dysregulation, Symptom Severity, and Antidepressant Treatment Response. Neuropsychopharmacology, 2010, 35, 1583-1592.	5.4	54
54	Polymorphisms in the GAD2 geneâ€region are associated with susceptibility for unipolar depression and with a risk factor for anxiety disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 1100-1109.	1.7	34

#	Article	IF	CITATIONS
55	The GABA transporter 1 (SLC6A1): a novel candidate gene for anxiety disorders. Journal of Neural Transmission, 2009, 116, 649-657.	2.8	52
56	Polymorphisms in the gene encoding the neuropeptide galanin are associated with HPA-axis dysregulation and symptome severity in major-depressive- and anxiety-disorder patients. Pharmacopsychiatry, 2009, 42, .	3.3	0
57	Polymorphisms in tryptophan hydroxylase 2 leading to decreased serotonergic activity contribute to elevated risk for metabolic syndrome in depression. Pharmacopsychiatry, 2009, 42, .	3.3	O
58	Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1196-1204.	1.7	101
59	Evidence for associations between PDE4D polymorphisms and a subtype of neuroticism. Molecular Psychiatry, 2008, 13, 831-832.	7.9	10
60	Association of polymorphisms in the angiotensin-converting enzyme gene with syndromal panic attacks. Molecular Psychiatry, 2008, 13, 242-243.	7.9	19
61	Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. European Journal of Neuroscience, 2008, 28, 389-398.	2.6	279
62	Polymorphisms in the galanin gene are associated with symptom–severity in female patients suffering from panic disorder. Journal of Affective Disorders, 2008, 105, 177-184.	4.1	48
63	Overweight and Obesity Affect Treatment Response in Major Depression. Biological Psychiatry, 2007, 62, 321-326.	1.3	172
64	Polymorphisms in the serotonin receptor gene HTR2A are associated with quantitative traits in panic disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 424-429.	1.7	60
65	Association of polymorphisms in P2RX7 and CaMKKb with anxiety disorders. Journal of Affective Disorders, 2007, 101, 159-168.	4.1	70
66	Association of a Met88Val diazepam binding inhibitor (DBI) gene polymorphism and anxiety disorders with panic attacks. Journal of Psychiatric Research, 2007, 41, 579-584.	3.1	31
67	Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. Pharmacopsychiatry, 2007, 40, .	3.3	0
68	Polymorphisms in the Leptin Gene are Associated with Resistance to Antidepressant Treatment and Lower Cognitive Performance in Depression. Pharmacopsychiatry, 2007, 40, .	3.3	0
69	A genome-wide association study in patients with panic and anxiety disorders. Pharmacopsychiatry, 2007, 40, .	3.3	0
70	Parkin Modulates Gene Expression in Control and Ceramide-Treated PC12 Cells. Molecular Biology Reports, 2006, 33, 13-32.	2.3	22
71	Regulation of the Hypothalamic–Pituitary–Adrenocortical System in Patients with Panic Disorder. Neuropsychopharmacology, 2006, 31, 2515-2522.	5.4	83
72	Responsiveness of the hypothalamic-pituitary-adrenocortical system in patients with agoraphobia and panic attacks. Pharmacopsychiatry, 2005, 38, .	3.3	0

#	Article	IF	CITATIONS
73	Polymorphisms in the serotonin receptor gene HTR2A modulate disease severity and susceptibility for anxiety disorders but not depression and are associated with specific personality traits. Pharmacopsychiatry, 2005, 38, .	3.3	0
74	Genetic implications of the endocannabinoid system in anxiety disorders versus depressive disorders: is there any evidence for the continuum hypothesis?. Pharmacopsychiatry, 2005, 38, .	3.3	O
75	Change in HPA system function predicts treatment response in depression. Pharmacopsychiatry, 2005, 38, .	3.3	0
76	GABA transporter1 (GAT1) inhibition mediates distinct emotional and cognitive processes and represents a possible treatment strategy compensating genetic polymorphisms in panic disorder. Pharmacopsychiatry, 2005, 38, .	3.3	0
77	Integrin linked kinase as a candidate downstream effector in proteinuria. FASEB Journal, 2001, 15, 1843-1845.	0.5	101